论文部分内容阅读
本文报道我院1975～1982年收治的胃癌170例进行了胃癌手术+术后化疗综合治疗和单纯手术(对照组)的随机对照研究,并作了5年随访。治疗结果:胃癌术后化疗综合治疗组的5年生存卒为40.2％(33/82),明显高于单纯手术(对照组)的21.6％(19/88)(P<0.01)。综合治疗组的中位生存期为39月,优于对照组18月。在胃癌根治术后化疗综合治疗组的5年生存率为56.4％(31/55),亦明显高于单纯根治术组的30.2％(19/63),经统计学处理有显著差异(P<0.01)。根治本后化疗综合治疗组的中位生存期为45月,明显高于单纯根治术组的23月。在Ⅱ～Ⅲ期胃癌的根治术后化疗综合治疗5年生存率达60.5％(26/43较单)纯根治术组的36.9％(17/46)明显提高(P<0.05)。我们认为胃癌根治术后辅助化疗可能是提高胃癌术后长期生存的有效方法。
In this paper, 170 cases of gastric cancer admitted to our hospital from 1975 to 1982 were included in a randomized controlled trial of gastric cancer surgery combined with postoperative chemotherapy and surgery alone (control group), and a 5-year follow-up was performed. Treatment outcome: The 5-year survival rate of postoperative chemotherapy in gastric cancer group was 40.2% (33/82), which was significantly higher than that of 21.6% (19/88) in simple surgery (control group) (P<0.01). The median survival time for the comprehensive treatment group was 39 months, which was superior to the control group for 18 months. The 5-year survival rate in the comprehensive chemotherapy group after radical gastrectomy for gastric cancer was 56.4% (31/55), which was also significantly higher than that of the simple radical surgery group (30.2%, 19/63). Statistically significant differences were observed (P< 0.01). The median survival of the radical chemotherapy group was 45 months, which was significantly higher than that of the simple radical surgery group. The 5-year survival rate of combined chemotherapy for stage II-III gastric cancer after radical resection was 60.5% (26/43 vs. single), and 36.9% (17/46) for radical radical surgery was significantly improved (P<0.05). We believe that adjuvant chemotherapy after radical gastrectomy may be an effective method to improve the long-term survival of gastric cancer.